Consequently, antibodies and small molecules targeting IGF-1 and IGF1R have been developed and tested in pre-clinical and clinical models, showing the potential to delay tumor growth and increase sensibility to CT and RT [50,51]. This evidence concerns the gene IGF1 and neoplasm.